Fluctuations in serogroup B meningococcal vaccine antigens prior to routine MenB vaccination in France.

ABSTRACT:

Background

Invasive meningococcal disease (IMD) of serogroup B is preventable by protein-based vaccines targeting one (Bivalent rLP2086 vaccine) or several variable proteins (4CMenB vaccine) at the bacterial surface. The 4CMenB was licensed in Europe in 2013 but has been recommended and reimbursed in France for infants over 2 months old since April 2022. The bivalent rLP2086 vaccine was licensed in Europe in 2017 for subjects of 10 years and older. Evaluating strain coverage and fluctuations prior to large scale vaccine use is highly informative.

Methods

We analysed invasive isolates at the French National Reference Centre for meningococci between 1975 and 2022. The 1691 recovered isolates were sequenced. We scored sex, and age groups of subjects. We also scored clonal compl

SUBMITTER: Falguieres M 

PROVIDER: S-EPMC11937567 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature